HPMC

Olmesartan medoxomil is an angiotensin II antagonist used as an antihypertensive drug which has poor oral bioavailability. Hence, an attempt was made to prepare and evaluate mucoadhesive buccal films containing Olmesartan medoxomil as model drug. Various mucoadhesive buccal films were prepared by employing HPMC alone, and in combination with Eudragit RL100, Carbapol 934, Ethyl cellulose were prepared by solvent casting method using ethanol , water and acetone as solvents, tween 80 as solubilising agent and glycerine as plasticizer. The prepared mucoadhesive buccal films were evaluated for their physic-chemical parameters such as thickness uniformity, weight uniformity, folding endurance, drug content , surface pH, swelling index, bioadhesion, percentage moisture loss and uptake, vapor transmission rate. The formulations exhibited good results. In – vitro drug release studies were conducted for OLM loaded films in phosphate buffer (pH 6.8) solution. The drug release was in the range of 67 to 90 % in 6hrs.. Stability studies were carried out with selected formulation. In- vivo release was evaluated in rabbits by patch test and it showed good correlation with the in-vitro release data. Drug release was found to be diffusion following zero order as per kinetic studies.

  The purpose of this research work was to develop and evaluate matrix-type transdermal therapeutic system containing Losartan potassium (LP) with different ratios of hydrophilic and hydrophobic polymeric combinations. Formulations were prepared by using solvent evaporation technique. Matrix type transdermal film of Losartan Potassium, antihypertensive drug were prepared using different polymers like Ethyl Cellulose, Hydroxy Propyl Methyl Cellulose and Eudragit RL100 in varied ratios. The present study aims to formulate and evaluate Transdermal film for sustained release of Losartan potassium. The results suggested no physicochemical incompatibility between the drug and the polymers. All formulations carried dimethyl sulfoxide as penetration enhancer and propylene glycol as plasticizer in chloroform and ethanol as solvent system. The diffusion studies were performed by using modified Franz diffusion cells. The formulation, F1 with combination of polymers (4:1) emerging to be ideal formulations for Losartan potassium. The developed transdermal films increase the efficacy of for the therapy of hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Physicochemical parameters were characterized. The permeability study indicates that the drug is suitable for Transdermal drug delivery. The film were evaluated for various parameters like Thickness, Water-Vapour permeability, Tensile Strength, moisture loss, moisture uptake, film folding endurance , Drug Content, flatness, surface pH, swellability, % elongation, skin irritation and Diffusion studies. The films were further evaluated by DSC to ensure uniform distribution of the drug and compatibility of drug with polymer. The Optimized formulation containing HPMC: Eudragit RL100 (4:1), with enhancer DMSO showed 87.13% drug release after 24 hours.

  The Aim of this study was preparation of dry powder formulation of rifampicin loaded polymeric microparticles as dry powder formulation for inhalation in effective tuberculosis treatment.The microparticles containing rifampicin (RIF) were prepared by spray drying method using different biocompatible polymers like chitosan and hydroxyl propyl methyl cellulose (HPMC) The microparticles and microparticle blend with coarse carrier Inhalac 230 were investigated for its aerosolization properties like emitted dose, Mass median aerodynamic diameter, Fine particle Fraction, Geometric Standard Deviation.The spray drying method produced wrinkle surfaced porous microparticles under the size range of 10µm. Mass median aerodynamic diameter obtained for all formulation ranged in 2.68 µm to 3.73 µm and Fine particle fraction in between 51.58 ± 5.36 to 72.74 ± 3.18. The lowest tapped density value obtained was 0.102 g/cm2 belong to formulation coded M1. In vitro deposition studies using cascade impactor showed emitted dose of > 90% for all batches. The polymeric microparticles produced by spray drying technique showed promising particle characteristics suitable for inhalation with Fine particle fraction (72.74 ± 3.18) of total emitted dose, after blending with lactose. The blending of the microparticles with Inhalac 230 allowed the Fine particle fraction values to increase by increasing the dispersibility of powder on inspiration. Key words: Rifampicin, Dry Powder Inhalation, Chitosan, HPMC, Interactive blend.

The present work reports the study of different Lamivudine (LAM): excipient formulations, in order to determine the effect of the polymer substitution and type of diluents on the drug-release mechanism. Seven formulations were prepared using either HPMC K15M alone or in combination with Ethyl Cellulose (EC). Release kinetics was evaluated by using United States Pharmacopeia (USP)-22 type I dissolution apparatus. The tablets were tested for their drug content, weight variation, hardness, thickness, tensile strength, friability, swelling and release ratio. Polymers HPMC K15M was found not to be appropriate for the preparation of modified release LAM hydrophilic matrix tablets, while combination of HPMC K15M and EC showed to be advantageous. The analysis of the release profiles in the light of distinct kinetic models (zero-order, first-order, Higuchi and Korsmeyer–Peppas) led to the conclusion that the concentration of polymer did not influence the release mechanism of the drug. The mean dissolution time (MDT) and t50% was determined, the highest MDT and t50% value being obtained for HPMC and EC formulations. Moreover, the drug-release process was not found to be influenced by the type of diluents, either MCC or DCP. Key words: Lamivudine, HPMC, Ethyl Cellulose